Find out more about the availability of cancer medicines in
- Enter in the search engine or select from the list
Select the type of cancer and see a full compilation of pharmaceutical therapies authorized by European Medicines Agency (EMA) in last 15 years and recommended by the European Society for Medical Oncology (or enter the medicine and check if it is reimbursed).
- Download or print out the list
Medicines increasing the chances of your successful recovery might be on the list.
- Consult the list with your doctor
Ask your doctor to verify the possible medicines and indicate the once which can be the most effective in your case. The list may also include non-reimbursed therapies. In such a situation contact us - we will help you find a solution.
Colon and rectum cancer
How to read the list?Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.
-
RamucirumabRamucirumab, in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.No reimbursementThe drug in this indication is not refundedESMOSubstance is recommended by ESMO.
-
PanitumumabPanitumumab is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC): ∙ in first-line in combination with FOLFOX or FOLFIRI. ∙ in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). ∙ as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
AfliberceptAflibercept in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
RegorafenibRegorafenib is indicated as monotherapy for the treatment of adult patients with - metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
Trifluridine / tipiracil hydrochlorideTrifluridine / Tipiracil Hydrochloride is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.